Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ense. 

Total operating costs and expenses in the second quarter of 2014 were $51.4 million as compared to $66.5 million in the second quarter of 2013.  Total operating costs and expenses in the first half of 2014 were $107.6 million as compared to $134.6 million in the first half of 2013.  Total operating costs and expenses decreased primarily as a result of decreased research and development (R&D) expense, as well as decreased cost of goods sold associated with decreased manufacturing activity.

Research and development expense in the second quarter of 2014 was $36.7 million as compared to $52.2 million in the second quarter of 2013.  For the first half of 2014, R&D expense was $75.0 million as compared to $97.8 million in the first half of 2013.  R&D expense was lower in the second quarter and first half of 2014 as compared to the same periods in 2013 primarily because of reduced expenses for the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, which completed enrollment in the third quarter of 2013. Additionally, R&D expense in the second quarter and first half of 2013 included costs related to the Phase 2 study of NKTR-181, which was completed in 2013.  These decreases in R&D expense in 2014 were partially offset by costs for the preparation for the start of Phase 3 for NKTR-181, the ongoing Phase 1 study of NKTR-171, and the continued production of devices for the ongoing Phase 3 studies of Amikacin Inhale.

General and administrative expense was $9.6 million in the second quarter of 2014 as compared to $9.2 million in the second quarter of 2013.  G&A expense in the first half of 2014 was $19.5 million as compared to $20.1 million in the first half of 2013.

Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.1 million and $10.5 million in the second quarter and first half of 2014, respectively, as compared to $
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Xencor, Inc. (NASDAQ: XNCR ), ... the treatment of autoimmune diseases, asthma and allergic diseases, ... S. Hata to its board of directors. ... corporate development is a tremendous asset to our board," ... executive officer of Xencor. "Xencor faces a range of ...
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation ... release its second quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, August ... quarter and other business developments. Interested parties ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... Promise As an Adjuvant for Vaccines,against Avian ... 07, 2007 /PRNewswire-FirstCall/ -- IR,BioSciences Holdings, Inc. ... vaccine adjuvant study being performed in,conjunction with ... above that induced by vaccine alone system.,These ...
... Calif., May 07, 2007 /PRNewswire-FirstCall/ --,Citing issues ... Conor Medsystems, LLC has concluded that the ... Restenosis),trial, the pivotal study for the CoStar ... its primary,endpoint. The trial did not identify ...
Cached Medicine Technology:IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 2IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 3IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 4Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 2Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 3Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent,Trial Conclusions 4
(Date:8/2/2015)... ... ... A new Phase I research study is looking at a vaccine that ... Kenneth G. Lucas, M.D. , chief of the division of pediatric hematology/oncology and stem ... Children’s Hospital and in the UofL Department of Pediatrics . Patients are ...
(Date:8/2/2015)... Orion, Clarkston, Metamora Michigan (PRWEB) , ... ... ... Pelvic Organ Prolapse (POP) results when the supportive muscles and connective tissues ... damaged. Causes of this weakness and damage include straining, heavy lifting, obesity, ...
(Date:8/1/2015)... In (PRWEB) , ... August 02, 2015 , ... ... month which will help the continuity of care for patients at this natural health ... of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our ...
(Date:8/1/2015)... ... August 01, 2015 , ... Western University ... trending profession” that comprises a growing percentage of U.S. physicians, and reflects the ... was one part of the message delivered by John W. Becher, DO, president ...
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins ... men and women often causing pain and discomfort. Those who spend a lot of ... and Northeast Houston Vein Center is doing what it can to create awareness and ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3
... more attention to choosing the doctor, not the device ... as a safe and long-lasting way to alleviate hip-related ... fails, the problem more often lies with surgical error ... , , Dislocation of the implant was the most common ...
... gene is a key to understanding, and perhaps killing, ... only to reawaken years later, researchers at The University ... the December Journal of Clinical Investigation . , ... ARHI acts as a switch for autophagy, or self-cannibalization, ...
... that Lewy bodies, clumps of aggregated proteins inside ... Parkinson,s disease and other neurodegenerative diseases. , The ... protein recycling and waste disposal, leading to the ... cells? , One possible answer: by breaking a ...
... supplementation was found to be effective in relieving pain ... chronic pancreatitis (CP), reports a new study in ... the pancreas in which patients experience abdominal pain (in ... Pain is the major problem in 90 percent of ...
... from presence of salicylic acid in study participants , , ... key component that gives aspirin its anti-inflammatory and pain-relieving ... own, a new study suggests. , Salicylic acid (SA) ... who had not taken aspirin recently -- especially vegetarians. ...
... organ improved odds, study shows , , WEDNESDAY, Dec. 31 ... donated kidney raised the chances of a successful transplant ... European researchers report. , The study, published in the ... of Medicine , got generally favorable reviews from American ...
Cached Medicine News:Health News:Surgeons Often Are Blamed When Hip Replacements Fail 2Health News:Surgeons Often Are Blamed When Hip Replacements Fail 3Health News:Dormant cancer cells rely on cellular self-cannibalization to survive 2Health News:Toxicity mechanism identified for Parkinson's disease 2Health News:Antioxidants offer pain relief in patients with chronic pancreatitis 2Health News:A Better Method of Kidney Storage 2Health News:A Better Method of Kidney Storage 3
... Strep A Test is a color immunochromatographic ... uses antibody labeled color particles coated at ... DLT allows greater sensitivity than the conventional ... the test procedure, a throat swab is ...
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
... term complications associated with diabetes continue to ... and quality of life of patients, in ... complications are known to be associated with ... that the level of haemoglobin A1c (HbA1c) ...
Medicine Products: